Chao (Daisy) Dai
About Chao (Daisy) Dai
Chao (Daisy) Dai is a Principal Scientist and Group Leader at Bristol Myers Squibb, specializing in mechanisms of cancer resistance. She has over a decade of experience in cancer research, with a strong background in biochemistry and molecular biology.
Current Position at Bristol Myers Squibb
Chao (Daisy) Dai is currently serving as Principal Scientist and Group Leader, Mechanisms of Cancer Resistance TRC at Bristol Myers Squibb. Based in Cambridge, Massachusetts, she leads a team focused on understanding mechanisms of cancer resistance. Her role involves orchestrating research efforts aimed at overcoming therapeutic resistance in cancer treatment, a critical area in oncology.
Previous Work Experience
Prior to her current role, Chao (Daisy) Dai worked as Senior Scientist and Group Leader, Mechanisms of Cancer Resistance TRC, also at Bristol Myers Squibb, from 2019 to 2021. Additionally, she gained valuable research experience as a Postdoctoral Research Fellow at Dana-Farber Cancer Institute in Boston, MA, from 2014 to 2019. During her time at Dana-Farber, she was involved in significant cancer research projects, adding to her extensive experience in the field.
Educational Background
Chao (Daisy) Dai holds a Doctor of Philosophy (PhD) in Oncology and Cancer Biology from Columbia University, where she studied from 2007 to 2013. Before that, she completed a Bachelor of Science (B.S.) in Biochemistry and Molecular Biology from The Hong Kong University of Science and Technology between 2003 and 2007. She also participated in a Study Abroad program in Biology at the University of California, Davis in 2006.
Expertise in Cancer Biology
With over a decade of research in cancer biology, Chao (Daisy) Dai has built extensive expertise in the mechanisms of cancer resistance. Her work blends academic insights and practical industry experience, providing her with a comprehensive understanding of biochemistry and molecular biology. This background underpins her current research efforts aimed at tackling therapeutic resistance in cancer.